Digital Health Tool for Improving Medication Adherence in Diabetes
Trial Summary
What is the purpose of this trial?
Latino individuals, the fastest growing ethnic minority population in the United States, have a higher prevalence of type 2 diabetes and diabetes-related complications, and are more likely to report inconsistent use of diabetes medications than non-Hispanic White individuals. The proposed project will test an interactive text message-based tool tailored to address barriers to taking diabetes medications that are relevant to Latino adults. If found feasible, acceptable, and usable, this intervention could serve as a scalable tool to improve diabetes management and reduce diabetes-related complications among Latino adults in the United States.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, since the study focuses on improving adherence to diabetes medications, it seems likely that you will continue taking them.
What data supports the effectiveness of the treatment ETAU, Enhanced Treatment As Usual, Standard Care, Usual Care, REACH-Es, REACH-Es, Rapid Education/Encouragement and Communications for Health - Español for improving medication adherence in diabetes?
Research shows that tailored diabetes education and support programs, especially those using digital tools and personalized coaching, can improve diabetes management and medication adherence. These approaches have been effective in enhancing diabetes knowledge and health outcomes, particularly among Latino populations who face language and literacy barriers.12345
Is the digital health tool for improving medication adherence in diabetes safe for humans?
How is the treatment ETAU, REACH-Es unique for improving medication adherence in diabetes?
Research Team
Jacqueline Seiglie
Principal Investigator
Massachusetts General Hospital
Eligibility Criteria
This trial is for Latino adults with type 2 diabetes who prefer to speak and read Spanish, have had suboptimal medication adherence, and an HbA1c level of ≥8.0% since 2018. Participants must be over 18, use a mobile phone with texting, and receive care at MGH-affiliated practices. Those with hearing issues or unable to handle text messages are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the REACH-Es intervention, including daily and weekly SMS related to diabetes management and adherence
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ETAU
- REACH-Es
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator